BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. It has clinical partnership with Nektar Therapeutics. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone475-238-6837
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
OptionableNot Optionable
BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions
What is BioXcel Therapeutics' stock symbol?
BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."
How were BioXcel Therapeutics' earnings last quarter?
BioXcel Therapeutics Inc (NASDAQ:BTAI) released its quarterly earnings results on Friday, November, 9th. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.05. View BioXcel Therapeutics' Earnings History.
When is BioXcel Therapeutics' next earnings date?
What price target have analysts set for BTAI?
5 brokerages have issued 12-month price objectives for BioXcel Therapeutics' stock. Their predictions range from $15.00 to $25.00. On average, they anticipate BioXcel Therapeutics' share price to reach $20.40 in the next year. This suggests a possible upside of 248.1% from the stock's current price. View Analyst Price Targets for BioXcel Therapeutics.
What is the consensus analysts' recommendation for BioXcel Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioXcel Therapeutics.
What are Wall Street analysts saying about BioXcel Therapeutics stock?
Here are some recent quotes from research analysts about BioXcel Therapeutics stock:
- 1. According to Zacks Investment Research, "BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. " (1/10/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We utilize a discounted cash flow (DCF)-based assessment, which yields a total rNPV of $335M for for BXCL701. We thus derive a total enterprise value of $455M, which translates into a price objective of $25.00 based on 18M fully-diluted shares outstanding as of end-3Q19." (1/4/2019)
- 3. Canaccord Genuity analysts commented, "We hosted BTAI’s CEO Vimal Mehta at our 2018 Boston, MA. CSO Frank Yocca, CMO Vincent O’Neill, and CFO Richard Steinhart were also in the audience. While we did not learn anything significantly new, we note the company appears very confident in its ability to hit its stated development timelines on its two product candidates: BXCL501 (sublingual dexmedetomidine), which is a neurology product for agitation that is in BXCL701, which is an oncology product for treatment-emergent neuroendocrine prostate cancer and pancreatic cancer. We continue to view the stock as an interesting oncology and neurology play, and are reiterating our BUY; see our recent initiation here for more details." (8/10/2018)
Has BioXcel Therapeutics been receiving favorable news coverage?
News stories about BTAI stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioXcel Therapeutics earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of BioXcel Therapeutics' key competitors?
Some companies that are related to BioXcel Therapeutics include Rigel Pharmaceuticals (RIGL), Insys Therapeutics (INSY), Keryx Biopharmaceuticals (KERX), Abeona Therapeutics (ABEO), Concert Pharmaceuticals (CNCE), Stemline Therapeutics (STML), Achillion Pharmaceuticals (ACHN), Kalvista Pharmaceuticals (KALV), BioDelivery Sciences International (BDSI), BIOFRONTERA AG/ADR (BFRA), OptiNose (OPTN), Lannett (LCI), Merus (MRUS), Dermira (DERM) and Albireo Pharma (ALBO).
Who are BioXcel Therapeutics' key executives?
BioXcel Therapeutics' management team includes the folowing people:
- Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 57)
- Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 61)
- Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 62)
- Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 49)
- Dr. David C. Hanley, Head of Global Pharmaceutical Devel. and Operations & VP
When did BioXcel Therapeutics IPO?
(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.
How do I buy shares of BioXcel Therapeutics?
Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioXcel Therapeutics' stock price today?
One share of BTAI stock can currently be purchased for approximately $5.86.
How big of a company is BioXcel Therapeutics?
BioXcel Therapeutics has a market capitalization of $87.77 million. BioXcel Therapeutics employs 6 workers across the globe.
What is BioXcel Therapeutics' official website?
How can I contact BioXcel Therapeutics?
BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]
MarketBeat Community Rating for BioXcel Therapeutics (NASDAQ BTAI)
MarketBeat's community ratings are surveys of what our community members think about BioXcel Therapeutics and other stocks. Vote "Outperform" if you believe BTAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
